High IDO expression within the tumor microenvironment contributes to immune evasion, facilitates tumor progression and metastasis, and is strongly associated with poor clinical outcomes and decreased overall survival in cancer patients (66–68). This evidence concerns the gene IDO1 and neoplasm.